Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Katherine Schultz, Gianluca Spitaleri, Filippo de Marinis, Benjamin Solomon, Beow Y. Yeap, Daniel Shao-Weng Tan, Alice T. Shaw, Tomasso De Pas, Chiara Lazzari, Luc Friboulet, Jeffrey A. Engelman, Justin F. Gainor, Aziah Ahmad
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(12)
Purpose: Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non–small cell lung cancer (NSCLC) that confer sensitivity to the ALK inhibitors crizotinib and ceritinib. To determine the outcome of sequential treatmen
Autor:
Su Jong Yu, Yoon Jun Kim, Dong Hyeon Lee, Jeong Min Lee, Kyung-Suk Suh, Yun Bin Lee, Eun Ju Cho, Jeong-Ju Yoo, Jung Hwan Yoon, Kion Kim, Won Mook Choi, Chung Yong Kim, Minjong Lee, Hyo-Suk Lee, Yuri Cho, Jeong Hoon Lee, Jung Hee Kwon
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(15)
Purpose: Insulin-like growth factor-I (IGF-I) reflects hepatic synthetic function and plays an important role in the development and progression of various cancers. In this study, we investigated whether pretreatment serum IGF-I levels predict time-t
Autor:
Annaelisa Tasciotti, Annette Pflugfelder, Leonardo Giovannoni, Claus Garbe, Filippo de Braud, Antonella Romanini, Gianluca Spitaleri, Dario Neri, Eveline Trachsel, Thomas Eigentler, Hans D. Menssen, Reinerio González-Iglesias, Kathrin Schwager, Valeria Lovato, Benjamin Weide, Manuela Kaspar
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose: L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of fibronectin, a tumor angiogenesis marker, and of human interleukin-2 (IL2). L19-IL2 delivers IL2 to the tumor site exploiting the selective expressio
Autor:
Sarah Eastty, Piotr Tomczak, Howard L. Kaufman, William Shingler, M. McDonald, Stuart Naylor, Robert J. Amato, Richard Harrop, Madusha Goonewardena, Cezary Szczylik, Jackie de Belin, Robert E. Hawkins, John A. Thompson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 16(22)
Purpose: The TroVax Renal Immunotherapy Survival Trial was a randomized, placebo-controlled phase III study that investigated whether modified vaccinia Ankara encoding the tumor antigen 5T4 (MVA-5T4) prolonged survival of patients receiving first-lin
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(19)
Purpose: To investigate tumor interstitial fluid pressure as a prognostic factor for recurrence-free survival in patients with cervical cancer following radiation therapy. Experimental Design: Tumor interstitial fluid pressure was measured in 55 cerv
Autor:
Ana Aparicio, Mark McNamara, David R. Gandara, George Somlo, Paul Frankel, Lucille Leong, James H. Doroshow, Carol Wong, David D. Smith, Thehang Luu, Robert J. Morgan, Dean Lim, Jana Portnow
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(21)
Purpose: The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer. The secondary goals included assessment of time to progression, evaluation of toxicities, and overall sur
Autor:
M. Roshni Ray, Marcin Skrzypski, David R. Gandara, Dan J. Raz, Miquel Taron, Rafael Rosell, Mark R. Segal, Biao He, David M. Jablons, Jaey Y. Kim
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(17)
Purpose: Clinical staging does not adequately risk stratify patients with early stage non–small cell lung cancer. We sought to generate a real-time PCR (RT-PCR)–based prognostic model in patients with early stage lung adenocarcinoma, the dominant
Autor:
Lokesh Jain, Clara C. Chen, Liang Cao, William D. Figg, James L. Gulley, Elizabeth C. Jones, Jürgen Venitz, Edwin M. Posadas, Philip M. Arlen, John Wright, William L. Dahut, Yunkai Yu, Jeanny B. Aragon-Ching, Charity D. Scripture, Seth M. Steinberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(1)
Purpose: To determine if sorafenib is associated with a 4-month probability of progression-free survival, which is consistent with 50%, as determined by clinical, radiographic, and prostate-specific antigen (PSA) criteria in patients with metastatic
Autor:
D Talbot, Claire Johnston, Emma Cattell, Anthe S. Zandvliet, S. Murray Yule, Paul Ellis, Léon Bosquee, Alwin D. R. Huitema, Joachim von Pawel, Martin Reck, Chris J. Norbury
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(6)
Purpose: The primary aim of this study was to measure the objective tumor response rate following treatment with indisulam [E7070; N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] as second-line therapy in patients with advanced non–small cell lung
Autor:
Yair Lotan, Seth P. Lerner, Amnon Vazina, Amit Gupta, Shahrokh F. Shariat, Patrick J. Bastian, Arthur I. Sagalowsky, Pierre I. Karakiewicz, Craig G. Rogers, Ganesh S. Palapattu, Gilad E. Amiel, Mark P. Schoenberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(22)
Aims: To develop multivariate nomograms that determine the probabilities of all-cause and bladder cancer–specific survival after radical cystectomy and to compare their predictive accuracy to that of American Joint Committee on Cancer (AJCC) stagin